BCL2L11 and non-small cell lung carcinoma: We found that aspirin increased Bim levels in osimertinib‐resistant NSCLC cells; additionally, when Bim expression was knocked down by Bim siRNA, the synergistic effects of aspirin and osimertinib were greatly reduced.